← Leaderboards

Yves Pommier

Basic Sciences

Google Scholar ↗PubMed ↗ORCID ↗

$0

Attributed

$0

Total exposure

0

Grants

0

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding mix

By agency

—

By mechanism

—

Top collaborators

No co-investigators on record.

Most similar at Basic Sciences

Same institution · by research overlap

David S Waugh$0
Peter P. Roller$0

Others in their field

Top investigators on “Pharmaceutical Preparations”

Sonia M Thomas · Research Triangle Institute$701,865,642
Tracy L Nolen · Research Triangle Institute$474,487,152
David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947

Research focus

Pharmaceutical PreparationsComplexClinical TrialsCollaborationsInhibitor/AntagonistMolecularEnzymesTopoisomerase InhibitorsDna RepairResponseCamptothecinSiteAntineoplastic AgentsDna DamagePharmacologyTopoisomeraseLaboratoriesTumorGenomicsCellsPathway InteractionsMutationClinicChromatin

Grant awards (87)

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$1,047,789

ZIA · FY2025 · CA · contact PI

TOP3B as host factor and drug target$898,104

ZIA · FY2025 · CA · contact PI

DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs$598,736

ZIA · FY2025 · CA · contact PI

Development Therapeutics Branch Clinical Trials$449,053

ZIA · FY2025 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$1,395,721

ZIA · FY2024 · CA · contact PI

TOP3B as host factor and drug target$1,196,333

ZIA · FY2024 · CA · contact PI

DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs$797,555

ZIA · FY2024 · CA · contact PI

Development Therapeutics Branch Clinical Trials$598,166

ZIA · FY2024 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$2,311,597

ZIA · FY2023 · CA · contact PI

DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs$1,050,726

ZIA · FY2023 · CA · contact PI

TOP3B as host factor and drug target$630,435

ZIA · FY2023 · CA · contact PI

Development Therapeutics Branch Clinical Trials$210,145

ZIA · FY2023 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$2,058,319

ZIA · FY2022 · CA · contact PI

DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs$935,600

ZIA · FY2022 · CA · contact PI

TOP3B as host factor and drug target$561,360

ZIA · FY2022 · CA · contact PI

Development Therapeutics Branch Clinical Trials$187,121

ZIA · FY2022 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$1,884,842

ZIA · FY2021 · CA · contact PI

DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs$856,746

ZIA · FY2021 · CA · contact PI

TOP3B as host factor and drug target$514,047

ZIA · FY2021 · CA · contact PI

Development Therapeutics Branch Clinical Trials$171,349

ZIA · FY2021 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$1,970,503

ZIA · FY2020 · CA · contact PI

DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs$895,684

ZIA · FY2020 · CA · contact PI

TOP3B as host factor and drug target for SARS-CoV-2 replicative cycle$537,410

ZIA · FY2020 · CA · contact PI

Development Therapeutics Branch Clinical Trials$179,137

ZIA · FY2020 · CA · contact PI

DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs$1,211,401

ZIA · FY2019 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$1,211,401

ZIA · FY2019 · CA · contact PI

Pharmacology of HIV Viral DNA and Retroviral Integrases$302,851

ZIA · FY2019 · CA · contact PI

Development Therapeutics Branch Clinical Trials$302,851

ZIA · FY2019 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$1,055,681

ZIA · FY2018 · CA · contact PI

DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs$1,055,681

ZIA · FY2018 · CA · contact PI

Pharmacology of HIV Viral DNA Retroviral Integrases$263,920

ZIA · FY2018 · CA · contact PI

Development Therapeutics Branch Clinical Trials$263,920

ZIA · FY2018 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$1,021,151

ZIA · FY2017 · CA · contact PI

DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs$1,021,151

ZIA · FY2017 · CA · contact PI

Pharmacology of HIV Viral DNA Retroviral Integrases$255,288

ZIA · FY2017 · CA · contact PI

Development Therapeutics Branch Clinical Trials$255,288

ZIA · FY2017 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$1,272,540

ZIA · FY2016 · CA · contact PI

DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs$980,918

ZIA · FY2016 · CA · contact PI

Pharmacology of HIV Viral DNA Retroviral Integrases$397,669

ZIA · FY2016 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$1,094,655

ZIA · FY2015 · CA · contact PI

DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs$843,796

ZIA · FY2015 · CA · contact PI

Pharmacology of HIV Viral DNA Retroviral Integrases$342,080

ZIA · FY2015 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$972,261

ZIA · FY2014 · CA · contact PI

DNA Topoisomerases as nuclear and mitochondrial targets of Anticancer Drugs$946,675

ZIA · FY2014 · CA · contact PI

Pharmacology of HIV Viral DNA Retroviral Integrases$639,646

ZIA · FY2014 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$957,460

ZIA · FY2013 · CA · contact PI

DNA Topoisomerases as Target of Action of Anticancer Drugs$932,263

ZIA · FY2013 · CA · contact PI

Pharmacology of HIV Viral DNA Retroviral Integrases$629,907

ZIA · FY2013 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$1,242,866

ZIA · FY2012 · CA · contact PI

DNA Topoisomerases as Target of Action of Anticancer Drugs$1,217,866

ZIA · FY2012 · CA · contact PI

Pharmacology of HIV Viral DNA Retroviral Integrases$608,932

ZIA · FY2012 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$1,157,850

ZIA · FY2011 · CA · contact PI

DNA Topoisomerases as Target of Action of Anticancer Drugs$1,132,850

ZIA · FY2011 · CA · contact PI

Pharmacology of HIV Viral DNA & Retroviral Integrases$566,425

ZIA · FY2011 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$1,240,655

ZIA · FY2010 · CA · contact PI

DNA Topoisomerases as Target of Action of Anticancer Drugs$1,215,655

ZIA · FY2010 · CA · contact PI

Pharmacology of HIV Viral DNA and Retroviral Integrases$607,827

ZIA · FY2010 · CA · contact PI

DNA Topoisomerases as Target of Action of Anticancer Drugs$1,103,955

ZIA · FY2009 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$1,103,955

ZIA · FY2009 · CA · contact PI

Pharmacology of HIV Viral DNA & Retroviral Integrases$551,978

ZIA · FY2009 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$799,704

Z01 · FY2008 · CA · contact PI

DNA Topoisomerases as Target of Action of Anticancer Drugs$799,704

Z01 · FY2008 · CA · contact PI

Pharmacology of HIV Viral DNA & Retroviral Integrases$399,852

Z01 · FY2008 · CA · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs$731,268

Z01 · FY2007 · CA · contact PI

DNA Topoisomerases as Target of Action of Anticancer Drugs$712,998

Z01 · FY2007 · CA · contact PI

Pharmacology of HIV Viral DNA & Retroviral Integrases$602,920

Z01 · FY2007 · CA · contact PI

Pharmacology of HIV Viral DNA & Retroviral Integrases$0

Z01 · FY2006 · BC · contact PI

DNA Topoisomerases as Target of Action of Anticancer Dru$0

Z01 · FY2006 · BC · contact PI

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targ$0

Z01 · FY2006 · BC · contact PI

DNA Topoisomerases as Target of Action of Anticancer Dru$0

Z01 · FY2005 · BC

Pharmacology of HIV Viral DNA &Retroviral Integrases$0

Z01 · FY2005 · BC

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targ$0

Z01 · FY2005 · BC

Pharmacology of HIV Viral DNA &Retroviral Integrases$0

Z01 · FY2004 · BC

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targ$0

Z01 · FY2004 · BC

DNA Topoisomerases as Target of Action of Anticancer Dru$0

Z01 · FY2004 · BC

DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targ$0

Z01 · FY2003 · BC

DNA Topoisomerases as Target of Action of Anticancer Dru$0

Z01 · FY2003 · BC

Pharmacology of HIV Viral DNA &Retroviral Integrases$0

Z01 · FY2003 · BC

Pharmacology of HIV Viral DNA &Retroviral Integrases$0

Z01 · FY2002 · BC

DNA Topoisomerases as Target of Action of Anticancer Dru$0

Z01 · FY2002 · BC

DNA Repair and Cell Cycle Checkpoints as Targets for Ant$0

Z01 · FY2002 · BC

DNA Topoisomerases as Target of Action of Anticancer Dru$0

Z01 · FY2001 · BC

Pharmacology of HIV Viral DNA &Retroviral Integrases$0

Z01 · FY2001 · BC

DNA Repair and Cell Cycle Checkpoints as Targets for Ant$0

Z01 · FY2001 · BC

Protein-Associated DNA Breaks as Indicator of Topoisomerase Inhibition$0

Z01 · FY2000 · BC

Pharmacology of HIV Viral DNA &Retroviral Integrases$0

Z01 · FY2000 · BC

DNA Topoisomerases as Target of Action of Anticancer Drugs$0

Z01 · FY2000 · BC